Status:
COMPLETED
Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this study the treatment process will be closely monitored using a novel imaging technology, a PET/CT scanner. PET stands for Positron Emission Tomography and in this case it will be combined with ...
Eligibility Criteria
Inclusion
- Histologic diagnosis of NHL:Any histology
- Stage I-IV
- Measurable disease by CT scan (gross disease measuring at least 2 cm in any one dimension)
- Planned radiation dose prescription \>=30 gy, \>=20 fractions, \>=3weeks duration
- Informed consent
- Previous chemotherapy is allowed, provided the above eligibility criteria are me
Exclusion
- To minimize effect from breathing motion, patients presenting with parenchymal lung tumours and tumours involving liver and stomach will be excluded
- Concurrent systemic chemotherapy (glucocorticoids when used alone is allowed)
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00188929
Start Date
August 1 2005
End Date
July 1 2009
Last Update
August 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9